Radiant Bio closes $35 million Series A funding for antibody platform

cafead

Administrator
Staff member
  • cafead   Sep 11, 2024 at 11:52: AM
via Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver transformative therapies for patients facing life-changing disease, announced it has closed a $35 million Series A financing. The round is co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures of Canada.

article source
 

<